Grufity logo
Grufity logo
APYX

APYX - Apyx Medical Corp Stock Price, Fair Value and News

$4.120.00 (0.00%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

25/100

APYX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

25/100

APYX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

APYX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APYX Price Action

Last 7 days

5.1%

Last 30 days

-11.6%

Last 90 days

34.6%

Trailing 12 Months

115.7%

APYX RSI Chart

APYX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APYX Valuation

Market Cap

172.5M

Price/Earnings (Trailing)

-18.86

Price/Sales (Trailing)

3.09

EV/EBITDA

-53.07

Price/Free Cashflow

-19.19

APYX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

APYX Fundamentals

APYX Revenue

Revenue (TTM)

55.9M

Rev. Growth (Yr)

32.45%

Rev. Growth (Qtr)

-34.83%

APYX Earnings

Earnings (TTM)

-9.1M

Earnings Growth (Yr)

49.2%

Earnings Growth (Qtr)

-59.82%

APYX Profitability

EBT Margin

-15.58%

Return on Equity

-71.3%

Return on Assets

-14.52%

Free Cashflow Yield

-5.21%

APYX Investor Care

Shares Dilution (1Y)

10.80%

Revenue & Growth

How Apyx Medical Corp generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202655.9M---
202547.3M46.5M47.9M52.8M
202450.5M49.0M48.5M48.1M
202344.2M47.4M50.3M52.3M
202252.4M51.4M48.7M44.5M
202131.4M38.3M43.2M48.5M
202027.6M25.3M24.6M27.7M
201918.8M21.8M25.7M28.2M
201812.0M13.4M14.4M16.6M
201730.5M23.5M16.1M10.2M
201631.2M33.2M35.4M36.6M
201527.3M27.7M28.7M29.5M
201424.4M25.3M26.3M27.7M
201326.6M25.2M24.4M23.7M
201226.0M26.6M27.0M27.7M
2011-25.7M25.5M25.4M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Apyx Medical Corp

APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures. The company's Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also offers hand pieces for open and laparoscopic procedures, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
 CEO
 WEBSITEapyxmedical.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES276

Apyx Medical Corp Frequently Asked Questions

APYX is the stock ticker symbol of Apyx Medical Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of Apyx Medical Corp is 172.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, APYX's PE ratio (Price to Earnings) is -18.86 and Price to Sales (PS) ratio is 3.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APYX PE ratio will change depending on the future growth rate expectations of investors.